Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
636 hedge funds and large institutions have $27.9B invested in Alexion Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 258 increasing their positions, 197 reducing their positions, and 53 closing their positions.
64% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 53
31% more repeat investments, than reductions
Existing positions increased: 258 | Existing positions reduced: 197
4% more funds holding
Funds holding: 611 → 636 (+25)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
1% less call options, than puts
Call options by funds: $218M | Put options by funds: $220M
4% less capital invested
Capital invested by funds: $29.1B → $27.9B (-$1.17B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$468M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$151M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$110M |
| 4 |
Renaissance Technologies
New York
|
+$108M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$100M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$459M |
| 2 |
JP Morgan Chase
New York
|
-$216M |
| 3 |
Jennison Associates
New York
|
-$158M |
| 4 |
Ninety One (UK)
London,
United Kingdom
|
-$132M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$90.2M |
ALXN Hedge Fund Activity: Q2 2019 in Review
636 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2019, worth a combined $27.9B — down 4% from $29.1B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new ALXN positions and 53 closed out — a net gain of 34 holders — while 258 added to existing stakes and 197 trimmed.
The largest buyer was Nuveen, adding an estimated $468M. The largest seller was Fidelity Investments, cutting an estimated $459M.
- 636 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2019, up from 611 in Q1 2019.
- Funds reported $27.9B of Alexion Pharmaceuticals stock for Q2 2019, down 4% quarter-over-quarter.
- 87 funds opened new Alexion Pharmaceuticals positions in Q2 2019 and 53 closed out, a net change of +34 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $468M added.
- The largest Alexion Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $459M sold.
Based on aggregated 13F filings for Q2 2019.